Fredun Pharmaceuticals : Q4 2024 Financial Quarterly Report : YoY Sales Up 47.02 %, QoQ Up 35.27 %

The comprehensive analytics outlining the performance and outlook of Fredun Pharmaceuticals Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Fredun Pharmaceuticals Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 47.02 %. However, it did see a marginal increase of 35.27 % from the previous quarter. Expenses ticked up slightly by 39.72 % quarter-on-quarter, aligning with the annual rise of 58.21 %. Operating profit, while down -15.11 % compared to last year, faced a quarter-on-quarter increase of 1.67 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -6.46 %, but a shrinkage of -2.92 % sequentially. Other income rose by 134.29 % compared to the last quarter, despite an annual growth of 1071.43 %. Interest expenses surged remarkably by 15.92 % from the previous quarter, yet the year-over-year increase remains at a moderate 23.1 %. Depreciation costs fell by -3.03 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 37.14 %. Profit before tax declined annually by -27.13 % but saw an increase from the preceding quarter by 1.22 %.
Tax expenses as a percentage of profits decreased slightly by -38.1 % compared to last year, with a more notable quarter-on-quarter decrease of -13.46 %. Net profit rose by 30.08 % year-on-year but experienced a 19.91 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 25.38 % but a quarterly rise of 19.8 %. In summary, Fredun Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Fredun Pharmaceuticals Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 47.02 % year-on-year growth, however, there was a minor increase of 35.27 % from the previous quarter. Expenses rose by 58.21 % compared to the previous year, with a 39.72 % increase quarter-on-quarter. Operating Profit dropped by -15.11 % annually, and saw a 1.67 % increase from the last quarter.
Net Profit showed yearly increase of 30.08 %, and experienced a 19.91 % increase from the previous quarter. Earnings Per Share (EPS) rose by 25.38 % annually, however rose by 19.8 % compared to the last quarter. In essence, while Fredun Pharmaceuticals Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.